Free Trial
→ The Great AI-Energy Collision (From Porter & Company) (Ad)

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, and Johnson & Johnson. Learn more about health care stocks.

Eli Lilly and Company logo

#1 - Eli Lilly and Company

NYSE:LLY - See Stock Forecast
Stock Price:
$788.35 (-$0.97)
Market Cap:
$748.40 billion
P/E Ratio:
85.2
Dividend Yield:
0.69%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1,007.94 (27.9% Upside)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Eli Lilly and Company Stock

Pros

  • The company reported a significant year-over-year revenue increase of 20.4%, indicating strong growth potential and demand for its products.
  • Eli Lilly and Co has a high return on equity of 71.08%, suggesting effective management and profitability, which can lead to higher shareholder returns.
  • The current stock price is $753.41, reflecting a recent increase, which may indicate positive market sentiment and potential for further appreciation.

Cons

  • The company recently missed earnings expectations, reporting $1.18 earnings per share compared to the consensus estimate of $1.52, which may raise concerns about its short-term performance.
  • With a price-to-earnings (P/E) ratio of 80.40, the stock may be considered overvalued, indicating that investors are paying a high price for each dollar of earnings, which could lead to a price correction.
  • The stock has a relatively high debt-to-equity ratio of 2.03, suggesting that the company is heavily reliant on debt financing, which can increase financial risk, especially in volatile markets.
UnitedHealth Group logo

#2 - UnitedHealth Group

NYSE:UNH - See Stock Forecast
Stock Price:
$608.38 (+$1.59)
Market Cap:
$559.88 billion
P/E Ratio:
39.6
Dividend Yield:
1.39%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 17 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$618.26 (1.6% Upside)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of UnitedHealth Group Stock

Pros

  • UnitedHealth Group recently reported a quarterly earnings per share (EPS) of $7.15, exceeding analysts' expectations of $7.00, indicating strong financial performance and effective management.
  • The company achieved a revenue of $100.82 billion for the quarter, surpassing estimates and reflecting a year-over-year growth of 9.2%, showcasing its robust business model and market demand.
  • With a current stock price of $602.29, UnitedHealth Group has shown resilience in the market, maintaining a strong position despite fluctuations.

Cons

  • Recent downgrades from analysts, including a reduction in target prices by several firms, may indicate concerns about the company's future performance and market conditions.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 39.12, which could suggest that it is overvalued compared to its earnings, potentially limiting upside for new investors.
  • UnitedHealth Group's debt-to-equity ratio of 0.74 indicates a moderate level of debt, which could pose risks in a rising interest rate environment or economic downturn.
Novo Nordisk A/S logo

#3 - Novo Nordisk A/S

NYSE:NVO - See Stock Forecast
Stock Price:
$106.12 (-$0.01)
Market Cap:
$476.22 billion
P/E Ratio:
34.3
Dividend Yield:
0.69%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$144.50 (36.2% Upside)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novo Nordisk A/S Stock

Pros

  • Recent upgrades in stock ratings, including a shift from "buy" to "strong-buy," indicate strong confidence from analysts in Novo Nordisk's future performance.
  • The current stock price is $105.24, reflecting a recent increase of 2.5%, which may suggest positive market sentiment and potential for further growth.
  • With a market capitalization of approximately $472.27 billion, Novo Nordisk is a major player in the pharmaceutical industry, providing stability and potential for long-term investment returns.

Cons

  • The stock has experienced a decline from its 1-year high of $148.15, which may raise concerns about its current valuation and market volatility.
  • Analysts have noted a decrease in price targets, with BMO Capital Markets lowering their target from $160.00 to $156.00, which could indicate a more cautious outlook.
  • With a P/E ratio of 33.22, the stock may be considered overvalued compared to industry peers, potentially limiting future price appreciation.
Johnson & Johnson logo

#4 - Johnson & Johnson

NYSE:JNJ - See Stock Forecast
Stock Price:
$155.39 (+$0.87)
Market Cap:
$374.12 billion
P/E Ratio:
22.5
Dividend Yield:
3.18%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 8 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$175.94 (13.2% Upside)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Johnson & Johnson Stock

Pros

  • Johnson & Johnson recently reported earnings per share of $2.42, exceeding analyst expectations of $2.21, indicating strong financial performance and effective management.
  • The stock is currently trading at $155.66, which is near its 1-year high of $168.85, suggesting potential for further appreciation in value.
  • Institutional investors hold 69.55% of the stock, reflecting strong confidence in the company's stability and growth prospects.

Cons

  • Despite recent growth, the stock has experienced volatility, with a significant drop from its 1-year high, which may concern risk-averse investors.
  • The company's debt-to-equity ratio stands at 0.45, which, while manageable, indicates some reliance on debt financing that could pose risks in economic downturns.
  • Recent selling by institutional investors, such as King Luther Capital Management Corp, which reduced its holdings by 1.4%, may signal a lack of confidence among some large stakeholders.
AbbVie logo

#5 - AbbVie

NYSE:ABBV - See Stock Forecast
Stock Price:
$183.09 (+$1.95)
Market Cap:
$323.55 billion
P/E Ratio:
63.6
Dividend Yield:
3.50%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 18 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$203.50 (11.1% Upside)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AbbVie Stock

Pros

  • AbbVie has a strong market position with a current stock price of $167.74, reflecting investor confidence and potential for growth.
  • The company recently reported earnings of $3.00 per share, exceeding analysts' expectations, which indicates robust financial performance and effective management.
  • AbbVie has received multiple upgrades from analysts, with Wells Fargo raising its price target to $195.00, suggesting a positive outlook and potential for stock appreciation.

Cons

  • The stock has experienced volatility, with a 52-week range between $137.14 and $207.32, indicating potential risks associated with price fluctuations.
  • AbbVie has a high debt-to-equity ratio of 9.64, which may raise concerns about financial leverage and the company's ability to manage its debt effectively.
  • Recent price target reductions from other analysts, such as Morgan Stanley lowering its target to $224.00, could signal caution among market experts regarding future performance.
Merck & Co., Inc. logo

#6 - Merck & Co., Inc.

NYSE:MRK - See Stock Forecast
Stock Price:
$103.04 (+$1.42)
Market Cap:
$260.65 billion
P/E Ratio:
21.6
Dividend Yield:
3.04%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 10 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$130.86 (27.0% Upside)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Merck & Co., Inc. Stock

Pros

  • Merck recently reported a quarterly earnings per share (EPS) of $1.57, exceeding analysts' expectations of $1.50, indicating strong financial performance.
  • The company has increased its quarterly dividend from $0.77 to $0.81, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 3.24%.
  • Merck's stock price is currently around $98.53, which is below its 1-year high of $134.63, suggesting potential for price appreciation as the market recovers.

Cons

  • Merck's revenue growth of 4.4% year-over-year is positive, but it may not be sufficient to meet the high expectations set by analysts, which could lead to volatility in stock performance.
  • The company's P/E ratio of 20.49 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent downgrades from analysts, including a reduction in price targets by firms like Morgan Stanley and Daiwa Capital Markets, may indicate a cautious outlook on the stock's near-term performance.
Novartis logo

#7 - Novartis

NYSE:NVS - See Stock Forecast
Stock Price:
$104.87 (+$1.06)
Market Cap:
$214.35 billion
P/E Ratio:
12.2
Dividend Yield:
2.35%
Consensus Rating:
Reduce (0 Strong Buy Ratings, 0 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$121.50 (15.9% Upside)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novartis Stock

Pros

  • Novartis AG recently reported earnings of $2.06 per share, exceeding analyst expectations of $1.94, indicating strong financial performance and effective management.
  • The company achieved a net margin of 35.96%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors looking for profitability.
  • With a current stock price of $102.94, Novartis AG is trading below its 52-week high of $120.92, suggesting potential for price appreciation as the market stabilizes.

Cons

  • One research analyst has rated Novartis AG with a sell rating, which may indicate potential concerns about the company's future performance.
  • The stock has a price-to-earnings (P/E) ratio of 11.93, which, while not excessively high, may suggest that the stock is fairly valued compared to its earnings, limiting upside potential.
  • Recent trading activity shows volatility, with shares trading down 0.4% recently, which could indicate market uncertainty regarding the stock's future direction.
Abbott Laboratories logo

#8 - Abbott Laboratories

NYSE:ABT - See Stock Forecast
Stock Price:
$118.96 (+$1.00)
Market Cap:
$206.33 billion
P/E Ratio:
36.2
Dividend Yield:
1.86%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 12 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$130.07 (9.3% Upside)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Abbott Laboratories Stock

Pros

  • Abbott Laboratories reported a strong quarterly earnings per share (EPS) of $1.21, exceeding the consensus estimate of $1.20, indicating robust financial performance and effective management.
  • The company achieved a revenue of $10.64 billion for the quarter, surpassing analysts' expectations of $10.55 billion, showcasing its ability to generate sales effectively.
  • Abbott Laboratories has a solid return on equity of 20.18%, which reflects its efficiency in generating profits from shareholders' equity, making it an attractive investment for those seeking strong returns.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 35.49, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Abbott Laboratories has a dividend payout ratio of 66.87%, which indicates that a significant portion of its earnings is being paid out as dividends, leaving less room for reinvestment in growth opportunities.
  • Despite recent positive performance, the stock has experienced fluctuations, with a 12-month low of $98.95, indicating potential volatility that could concern risk-averse investors.
AstraZeneca logo

#9 - AstraZeneca

NASDAQ:AZN - See Stock Forecast
Stock Price:
$67.20 (+$0.84)
Market Cap:
$205.76 billion
P/E Ratio:
32.2
Dividend Yield:
1.48%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 7 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$89.75 (33.6% Upside)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AstraZeneca Stock

Pros

  • AstraZeneca has received multiple upgrades from brokerages, indicating positive sentiment in the market. For instance, Deutsche Bank upgraded the stock from a "sell" to a "hold" rating, which can suggest a more favorable outlook for potential investors.
  • The company has a strong market capitalization of approximately $199.99 billion, reflecting its stability and size in the biopharmaceutical sector, which can be appealing to investors looking for established companies.
  • Current stock price is $64.50, which is significantly lower than its 12-month high of $87.68. This may present a buying opportunity for investors looking to enter at a lower price point.

Cons

  • The stock has experienced a recent decline, trading down 0.3% to $64.50, which may indicate short-term volatility and potential risks for investors.
  • AstraZeneca's P/E ratio is currently at 31.09, which is relatively high compared to industry averages, suggesting that the stock may be overvalued and could face downward pressure.
  • The company has a quick ratio of 0.69 and a current ratio of 0.89, indicating potential liquidity issues, which could affect its ability to meet short-term obligations.
Thermo Fisher Scientific logo

#10 - Thermo Fisher Scientific

NYSE:TMO - See Stock Forecast
Stock Price:
$521.67 (+$8.69)
Market Cap:
$199.54 billion
P/E Ratio:
32.7
Dividend Yield:
0.30%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$649.33 (24.5% Upside)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Thermo Fisher Scientific Stock

Pros

  • The company has a strong dividend yield of 0.30%, which can provide a steady income stream for investors. The annualized dividend is $1.56, and the payout ratio is only 9.78%, indicating that the company retains a significant portion of its earnings for growth.
  • Recent analyst ratings show a positive outlook, with 17 analysts assigning a buy rating and one a strong buy rating. This suggests strong confidence in the company's future performance.
  • Thermo Fisher Scientific Inc. has a current stock price around $610.00, which is seen as a reasonable entry point given the company's growth potential and recent price target adjustments by analysts.

Cons

  • Despite the positive outlook, some analysts have recently lowered their price targets, indicating potential concerns about short-term performance or market conditions.
  • The stock has a relatively low dividend payout ratio, which, while indicating retained earnings for growth, may also suggest that the company is not prioritizing immediate returns to shareholders.
  • Market volatility can impact the stock price, and with recent adjustments in analyst ratings, there may be uncertainty regarding the company's ability to meet growth expectations.
Intuitive Surgical logo

#11 - Intuitive Surgical

NASDAQ:ISRG - See Stock Forecast
Stock Price:
$538.55 (-$3.55)
Market Cap:
$191.82 billion
P/E Ratio:
86.6
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 14 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$526.06 (-2.3% Downside)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Intuitive Surgical Stock

Pros

  • Intuitive Surgical, Inc. reported strong quarterly earnings, with earnings per share (EPS) of $1.56, exceeding the consensus estimate of $1.24. This indicates robust financial performance and potential for future growth.
  • The stock is currently priced at $538.79, which is near its 1-year high of $551.78, suggesting strong market confidence and potential for further appreciation.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with an average target price of $524.61, indicating positive sentiment among market experts.

Cons

  • Insider selling has been significant, with over 91,178 shares sold in the last quarter, which may indicate a lack of confidence from those closest to the company.
  • The stock has a high price-to-earnings (P/E) ratio of 86.63, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite strong earnings, the company has a relatively low return on equity of 13.41%, which may raise concerns about how effectively it is using shareholder equity to generate profits.
Amgen logo

#12 - Amgen

NASDAQ:AMGN - See Stock Forecast
Stock Price:
$280.07 (+$0.06)
Market Cap:
$150.55 billion
P/E Ratio:
35.9
Dividend Yield:
3.06%
Consensus Rating:
Hold (1 Strong Buy Ratings, 11 Buy Ratings, 13 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$323.05 (15.3% Upside)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Amgen Stock

Pros

  • Amgen Inc. recently reported earnings per share of $5.58, exceeding the consensus estimate of $5.11, indicating strong financial performance and effective management.
  • The company has shown impressive revenue growth, with a year-over-year increase of 23.2%, reflecting its ability to expand its market presence and product offerings.
  • Amgen Inc. has a current stock price of $287.87, which may present a buying opportunity for investors looking for growth potential, especially given the average target price of $333.57 set by analysts.

Cons

  • Despite strong earnings, Amgen Inc. has a high debt-to-equity ratio of 7.55, which may indicate financial risk and could affect its ability to invest in future growth opportunities.
  • One analyst has issued a sell rating on the stock, highlighting potential concerns about its future performance compared to peers in the biotechnology sector.
  • The company's dividend payout ratio is currently at 115.24%, suggesting that it is paying out more in dividends than it is earning, which could be unsustainable in the long term.
Stryker logo

#13 - Stryker

NYSE:SYK - See Stock Forecast
Stock Price:
$388.14 (-$1.57)
Market Cap:
$148.56 billion
P/E Ratio:
41.6
Dividend Yield:
0.82%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$393.65 (1.4% Upside)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Stryker Stock

Pros

  • Stryker Co. recently reported earnings per share (EPS) of $2.87, exceeding analysts' expectations of $2.77, indicating strong financial performance and effective management.
  • The company achieved a revenue of $5.49 billion for the latest quarter, surpassing estimates and reflecting an 11.9% year-over-year growth, showcasing its robust market position.
  • Current stock price is $390.08, which is close to its 12-month high of $392.70, suggesting strong investor confidence and potential for further appreciation.

Cons

  • The stock has experienced insider selling, with corporate insiders selling a total of 67,381 shares worth approximately $24.8 million in the last 90 days, which may signal a lack of confidence among those closest to the company.
  • Stryker Co. has a relatively high price-to-earnings (P/E) ratio of 41.81, which could indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The company has a debt-to-equity ratio of 0.66, which, while manageable, suggests that it is not entirely free from debt, potentially impacting its financial flexibility in adverse conditions.
Pfizer logo

#14 - Pfizer

NYSE:PFE - See Stock Forecast
Stock Price:
$25.83 (+$0.06)
Market Cap:
$146.38 billion
P/E Ratio:
34.9
Dividend Yield:
6.42%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 5 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$32.92 (27.5% Upside)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Pfizer Stock

Pros

  • Pfizer Inc. reported a strong quarterly earnings result with earnings per share (EPS) of $1.06, significantly exceeding analysts' expectations of $0.64. This indicates robust financial performance and potential for future growth.
  • The company achieved a revenue of $17.70 billion for the quarter, which is a 31.2% increase year-over-year, showcasing its ability to grow sales effectively.
  • Pfizer Inc. has a current stock price of $25.06, which is near its 12-month low of $24.48, potentially offering a buying opportunity for investors looking for value.

Cons

  • Despite recent earnings growth, Pfizer Inc. has a high payout ratio of 227.03%, indicating that it pays out more in dividends than it earns, which could be unsustainable in the long run.
  • The stock has experienced volatility, with a beta of 0.67, suggesting that it may not be as stable as some investors prefer, especially in uncertain market conditions.
  • There is a mixed outlook from analysts, with one sell rating and several hold ratings, indicating that not all market participants are confident in the stock's future performance.
Boston Scientific logo

#15 - Boston Scientific

NYSE:BSX - See Stock Forecast
Stock Price:
$90.76 (+$0.55)
Market Cap:
$133.76 billion
P/E Ratio:
75.0
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 19 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$93.39 (2.9% Upside)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Boston Scientific Stock

Pros

  • Boston Scientific Co. has shown strong financial performance, reporting a revenue of $4.21 billion for the latest quarter, exceeding analysts' expectations of $4.04 billion. This indicates robust demand for its medical products.
  • The company recently achieved earnings per share (EPS) of $0.63, surpassing the consensus estimate of $0.59. A higher EPS often reflects a company's profitability and can lead to increased investor confidence.
  • With a current stock price of $91.54, Boston Scientific Co. has demonstrated a significant increase in value, reflecting positive market sentiment and potential for further growth.

Cons

  • Insider selling has been notable, with insiders selling 309,270 shares worth over $26 million in the last 90 days. This could signal a lack of confidence in the company's future performance from those who are most familiar with it.
  • The stock has a high price-to-earnings (P/E) ratio of 74.52, which may indicate that the stock is overvalued compared to its earnings. High P/E ratios can suggest that investors are expecting high growth rates, which may not materialize.
  • Despite recent upgrades from analysts, there are still four analysts who have rated the stock as a hold, indicating some uncertainty about its future performance.
Sanofi logo

#16 - Sanofi

NASDAQ:SNY - See Stock Forecast
Stock Price:
$48.72 (+$0.44)
Market Cap:
$123.64 billion
P/E Ratio:
24.9
Dividend Yield:
3.06%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$57.50 (18.0% Upside)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Sanofi Stock

Pros

  • Recent institutional investments, such as China Universal Asset Management Co. Ltd. increasing its stake by 69.9%, indicate strong confidence in Sanofi's future performance.
  • Analysts have recently upgraded their ratings on Sanofi, with Citigroup assigning a "strong-buy" rating, suggesting positive market sentiment and potential for stock price appreciation.
  • The current stock price is $53.83, which is near its 12-month high of $58.97, indicating a strong performance and potential for further growth.

Cons

  • Despite recent upgrades, the average price target from analysts is $57.50, which indicates limited upside potential from the current stock price.
  • Sanofi's price-to-earnings (P/E) ratio of 27.46 is relatively high, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The company has experienced fluctuations in stock price, with a recent drop to $49.51, indicating potential instability in the short term.
Bristol-Myers Squibb logo

#17 - Bristol-Myers Squibb

NYSE:BMY - See Stock Forecast
Stock Price:
$59.27 (+$0.53)
Market Cap:
$120.21 billion
Dividend Yield:
4.08%
Consensus Rating:
Hold (2 Strong Buy Ratings, 2 Buy Ratings, 14 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$54.07 (-8.8% Downside)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Bristol-Myers Squibb Stock

Pros

  • The company has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • Recent analyst upgrades, such as from Daiwa Capital Markets and Leerink Partners, indicate positive market sentiment and potential for stock price appreciation.
  • The current stock price is around $54.07, which is considered reasonable given the company's strong product pipeline and market position.

Cons

  • Some analysts, including those from Morgan Stanley, have assigned an "underweight" rating, indicating concerns about the stock's performance relative to the market.
  • There are two sell ratings among analysts, suggesting that a portion of the market may have reservations about the company's future growth prospects.
  • Potential competition from other pharmaceutical companies could impact Bristol-Myers Squibb's market share and pricing power, particularly in key therapeutic areas.
Vertex Pharmaceuticals logo

#18 - Vertex Pharmaceuticals

NASDAQ:VRTX - See Stock Forecast
Stock Price:
$464.56 (-$2.51)
Market Cap:
$119.64 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 8 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$504.38 (8.6% Upside)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Vertex Pharmaceuticals Stock

Pros

  • Vertex Pharmaceuticals Incorporated recently reported earnings per share of $4.38, exceeding analysts' expectations of $3.61, indicating strong financial performance and effective management.
  • The company's revenue for the latest quarter was $2.77 billion, surpassing expectations and reflecting an 11.6% year-over-year growth, showcasing its ability to expand its market presence.
  • As of the latest trading session, the stock price is $448.01, which may present a buying opportunity for investors looking for growth in the biotechnology sector.

Cons

  • The company has a negative return on equity of 1.91% and a negative net margin of 4.52%, which may raise concerns about profitability and operational efficiency.
  • Vertex Pharmaceuticals Incorporated has a PE ratio of -226.57, indicating that the company is currently not generating profits relative to its stock price, which can be a red flag for potential investors.
  • Insider selling has occurred, with significant shares sold by the Chairman and a Director, which could signal a lack of confidence in the company's short-term performance.
Gilead Sciences logo

#19 - Gilead Sciences

NASDAQ:GILD - See Stock Forecast
Stock Price:
$92.41 (+$1.06)
Market Cap:
$115.17 billion
P/E Ratio:
1,026.8
Dividend Yield:
3.40%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 11 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$95.41 (3.2% Upside)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Gilead Sciences Stock

Pros

  • The stock is currently priced at approximately $83.78, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Recent analyst upgrades have increased price targets for Gilead Sciences, Inc., with JPMorgan Chase & Co. raising their target to $105.00, indicating strong potential for price appreciation.
  • Gilead Sciences, Inc. has a diverse portfolio of medicines addressing unmet medical needs, which can lead to sustained revenue growth and market presence.

Cons

  • The payout ratio is extremely high at 3,422.22%, indicating that the company is paying out significantly more in dividends than it earns, which may not be sustainable.
  • Insider sales have occurred recently, which could signal a lack of confidence in the stock's short-term performance.
  • Despite positive analyst ratings, the stock has a mixed outlook with many analysts maintaining a "hold" rating, suggesting caution among investors.
Medtronic logo

#20 - Medtronic

NYSE:MDT - See Stock Forecast
Stock Price:
$86.29 (+$0.61)
Market Cap:
$110.66 billion
P/E Ratio:
26.4
Dividend Yield:
3.27%
Consensus Rating:
Hold (1 Strong Buy Ratings, 6 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$95.27 (10.4% Upside)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Medtronic Stock

Pros

  • Medtronic plc reported a quarterly earnings per share (EPS) of $1.26, exceeding the consensus estimate of $1.25, indicating strong financial performance and effective management.
  • The company achieved a revenue of $8.40 billion for the quarter, surpassing analyst expectations of $8.27 billion, which reflects robust demand for its medical technologies.
  • With a market capitalization of $108.63 billion, Medtronic plc is a significant player in the medical technology sector, providing stability and potential for growth.

Cons

  • The company has a price-to-earnings (PE) ratio of 25.91, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
  • Medtronic plc has a debt-to-equity ratio of 0.51, indicating a moderate level of debt, which could pose risks if the company faces financial challenges.
  • The stock has a beta of 0.84, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
The Cigna Group logo

#21 - The Cigna Group

NYSE:CI - See Stock Forecast
Stock Price:
$336.55 (+$1.55)
Market Cap:
$93.61 billion
P/E Ratio:
31.8
Dividend Yield:
1.68%
Consensus Rating:
Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$394.64 (17.3% Upside)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of The Cigna Group Stock

Pros

  • The Cigna Group reported a strong quarterly earnings per share of $7.51, exceeding the consensus estimate of $7.22, indicating robust financial performance and effective management.
  • With a revenue of $63.70 billion for the quarter, which is a 29.8% increase year-over-year, The Cigna Group demonstrates significant growth potential, making it an attractive option for investors seeking growth stocks.
  • The current stock price is $323.36, which is below several analysts' target prices, suggesting potential for price appreciation as the stock may be undervalued relative to its projected performance.

Cons

  • The stock has a relatively high P/E ratio of 30.44, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite strong revenue growth, the net margin of 1.31% is relatively low, suggesting that the company may face challenges in converting sales into actual profit, which could impact future earnings.
  • The company has a debt-to-equity ratio of 0.71, indicating a moderate level of debt, which could pose risks if interest rates rise or if the company faces financial difficulties.
Elevance Health logo

#22 - Elevance Health

NYSE:ELV - See Stock Forecast
Stock Price:
$402.80 (+$0.84)
Market Cap:
$93.42 billion
P/E Ratio:
14.7
Dividend Yield:
1.60%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 12 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$539.20 (33.9% Upside)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Regeneron Pharmaceuticals logo

#23 - Regeneron Pharmaceuticals

NASDAQ:REGN - See Stock Forecast
Stock Price:
$754.87 (+$1.84)
Market Cap:
$82.95 billion
P/E Ratio:
18.7
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 16 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1,107.29 (46.7% Upside)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Regeneron Pharmaceuticals Stock

Pros

  • The current stock price is $757.96, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. has a strong market capitalization of approximately $83.29 billion, indicating a solid financial foundation and stability in the market.
  • The company has received multiple "buy" ratings from analysts, with a consensus rating of "Moderate Buy," suggesting positive sentiment and potential for stock appreciation.

Cons

  • Recent downgrades from analysts, including a reduction in target prices, may indicate a bearish outlook on the stock's short-term performance.
  • The stock has experienced a significant decrease in value from its 1-year high of $1,211.20, which could raise concerns about its volatility and future price stability.
  • One research analyst has issued a sell rating, which could signal potential risks associated with the company's performance and market conditions.
HCA Healthcare logo

#24 - HCA Healthcare

NYSE:HCA - See Stock Forecast
Stock Price:
$325.35 (-$3.60)
Market Cap:
$82.41 billion
P/E Ratio:
14.6
Dividend Yield:
0.81%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 11 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$380.29 (16.9% Upside)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of HCA Healthcare Stock

Pros

  • HCA Healthcare, Inc. has a strong market capitalization of approximately $86.87 billion, indicating a robust financial position and stability in the healthcare sector.
  • The company recently announced a quarterly dividend of $0.66 per share, which translates to an annualized dividend of $2.64 and a yield of 0.77%. This consistent dividend payment can provide a steady income stream for investors.
  • Recent analyst upgrades, including a price target increase from Oppenheimer to $400.00, suggest positive market sentiment and potential for stock price appreciation.

Cons

  • Insider selling has been notable, with a total of 15,155 shares sold in the last three months, which may indicate a lack of confidence among company executives regarding future performance.
  • The stock has experienced a decline, trading down $2.55 recently, which could signal potential volatility and risk for investors.
  • HCA Healthcare, Inc. has a relatively high debt-to-equity ratio of 48.71, suggesting that the company relies significantly on debt financing, which can be risky in fluctuating market conditions.
McKesson logo

#25 - McKesson

NYSE:MCK - See Stock Forecast
Stock Price:
$626.54 (+$1.53)
Market Cap:
$79.53 billion
P/E Ratio:
32.4
Dividend Yield:
0.45%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$631.57 (0.8% Upside)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of McKesson Stock

Pros

  • McKesson Co. reported earnings per share of $7.07 for the latest quarter, surpassing analysts' expectations of $6.88, indicating strong financial performance and effective management.
  • The company achieved a revenue of $93.65 billion during the quarter, significantly exceeding the forecast of $89.33 billion, showcasing robust growth and demand for its services.
  • Currently, McKesson Co. is trading at $606.29, reflecting a strong market position and investor confidence, especially given its 12-month high of $637.51.

Cons

  • The company has a negative return on equity of 207.50%, which may raise concerns about its ability to generate profit from shareholders' equity.
  • Despite strong revenue growth, McKesson Co. has a net margin of only 0.77%, indicating that a small percentage of revenue is converted into profit, which could limit overall profitability.
  • Recent insider selling, including a significant transaction by the CEO, may signal a lack of confidence in the company's short-term performance.
Zoetis logo

#26 - Zoetis

NYSE:ZTS - See Stock Forecast
Stock Price:
$176.74 (+$1.04)
Market Cap:
$79.27 billion
P/E Ratio:
33.2
Dividend Yield:
0.98%
Consensus Rating:
Buy (1 Strong Buy Ratings, 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$221.44 (25.3% Upside)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Zoetis Stock

Pros

  • Zoetis Inc. recently reported earnings of $1.58 per share, exceeding analysts' expectations of $1.46, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 11.6%, reaching $2.40 billion, which reflects robust growth and demand for its products.
  • As of the latest trading session, Zoetis Inc. shares are priced at $175.57, which may present a buying opportunity for investors looking for growth in the animal health sector.

Cons

  • The stock has experienced a decline of 0.5% recently, which may indicate short-term volatility and investor uncertainty.
  • With a price-to-earnings (P/E) ratio of 33.00, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
  • The company has a debt-to-equity ratio of 1.26, suggesting a higher level of debt relative to equity, which could pose risks in a rising interest rate environment.
GSK logo

#27 - GSK

NYSE:GSK - See Stock Forecast
Stock Price:
$34.32 (+$0.30)
Market Cap:
$71.13 billion
P/E Ratio:
22.3
Dividend Yield:
4.47%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 0 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$43.25 (26.0% Upside)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GSK Stock

Pros

  • GSK plc has recently seen significant institutional investment, with firms like Natixis Advisors LLC increasing their holdings by 20% in the third quarter, indicating strong confidence in the company's future performance.
  • The stock is currently trading at $33.55, which is near its 52-week low of $32.83, potentially offering a buying opportunity for investors looking for value.
  • GSK has received positive ratings from analysts, with several upgrades, including a "strong-buy" rating from Argus, suggesting that market sentiment is favorable.

Cons

  • Despite recent positive ratings, GSK has also faced downgrades, such as from Guggenheim, which may indicate volatility in investor sentiment.
  • The stock has a price-to-earnings ratio of 21.88, which is relatively high compared to industry averages, suggesting that it may be overvalued at current levels.
  • GSK's stock has experienced fluctuations, with a 52-week high of $45.92, indicating potential instability and risk for investors.
Aetna logo

#28 - Aetna

NYSE:AET - See Stock Forecast
Stock Price:
$212.70
Market Cap:
$69.64 billion
P/E Ratio:
21.6
Dividend Yield:
0.94%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Aetna Stock

Pros

  • Aetna Inc. has recently expanded its network by partnering with Clarity Clinic, enhancing its offerings in Partial Hospitalization Programs (PHP) and Intensive Outpatient Programs (IOP), which could attract more customers seeking mental health services.
  • The company operates in a diverse range of segments, including Health Care, Group Insurance, and Large Case Pensions, providing a stable revenue stream and reducing risk associated with reliance on a single market.
  • Aetna Inc. offers a variety of health plans, including Medicare and Medicaid products, which are essential as the population ages and demand for these services increases, potentially leading to higher revenues.

Cons

  • The health care industry is highly regulated, and changes in government policies or regulations could negatively impact Aetna Inc.'s operations and profitability.
  • Competition in the health care benefits market is intense, with numerous players vying for market share, which could pressure Aetna Inc.'s pricing and margins.
  • Economic downturns can lead to higher unemployment rates, which may reduce the number of employer-sponsored health plans, adversely affecting Aetna Inc.'s revenue.
Becton, Dickinson and Company logo

#29 - Becton, Dickinson and Company

NYSE:BDX - See Stock Forecast
Stock Price:
$221.96 (-$2.29)
Market Cap:
$64.16 billion
P/E Ratio:
37.4
Dividend Yield:
1.69%
Consensus Rating:
Buy (0 Strong Buy Ratings, 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$283.00 (27.5% Upside)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Becton, Dickinson and Company Stock

Pros

  • Becton, Dickinson and Company recently reported earnings per share of $3.81, exceeding analyst expectations of $3.77, indicating strong financial performance and effective management.
  • The company has increased its quarterly dividend from $0.95 to $1.04, reflecting a commitment to returning value to shareholders and a healthy payout ratio of 70.03%.
  • Recent upgrades from multiple analysts, including Citigroup raising its rating to "buy" and increasing the price target to $275, suggest positive market sentiment and potential for stock appreciation.

Cons

  • Despite recent growth, the company's net margin of 8.55% may indicate challenges in maintaining profitability compared to industry peers.
  • Analysts have mixed opinions, with Raymond James recently lowering its price target from $275 to $270, which could signal concerns about future performance.
  • Institutional investors own 86.97% of the stock, which may lead to volatility if large shareholders decide to sell, impacting stock price stability.
Allergan logo

#30 - Allergan

NYSE:AGN - See Stock Forecast
Stock Price:
$193.02
Market Cap:
$63.50 billion
Dividend Yield:
1.53%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Allergan Stock

Pros

  • Allergan plc has a diverse portfolio of products across various therapeutic areas, including medical aesthetics, eye care, and neuroscience, which can provide stability and growth potential in different market conditions.
  • The company is actively developing innovative treatments, such as RST-001, a novel gene therapy for retinitis pigmentosa, which could position it as a leader in emerging therapeutic areas and attract significant market interest.
  • Allergan plc's recent collaborations with companies like Editas Medicine, Inc. enhance its research capabilities and may lead to breakthrough therapies, potentially increasing its market share and revenue streams.

Cons

  • Allergan plc faces intense competition in the pharmaceutical industry, which can lead to pricing pressures and reduced profit margins on its products.
  • The company is heavily reliant on a few key products for a significant portion of its revenue, making it vulnerable to market fluctuations and changes in consumer preferences.
  • Regulatory challenges and the lengthy approval process for new drugs can delay product launches, impacting potential revenue growth and investor confidence.
Shire logo

#31 - Shire

NASDAQ:SHPG - See Stock Forecast
Stock Price:
$179.20
Market Cap:
$54.71 billion
P/E Ratio:
11.8
Dividend Yield:
0.19%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Express Scripts logo

#32 - Express Scripts

NASDAQ:ESRX - See Stock Forecast
Stock Price:
$92.33
Market Cap:
$52.06 billion
P/E Ratio:
13.0
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Express Scripts Stock

Pros

  • Express Scripts Holding operates a robust pharmacy benefit management (PBM) segment, which is essential for managing prescription drug benefits for various health plans, indicating a strong market position.
  • The company has a diverse range of services, including specialized pharmacy care and digital consumer health solutions, which can attract a wide array of clients, enhancing revenue potential.
  • Recent developments include ongoing litigation against the FTC, which could potentially lead to favorable outcomes that may positively impact stock performance and investor confidence.

Cons

  • The ongoing lawsuit against the FTC introduces uncertainty, which could lead to volatility in stock prices and investor sentiment.
  • As a company operating in the healthcare sector, Express Scripts Holding faces regulatory challenges that could impact its operations and profitability.
  • Competition in the pharmacy benefit management space is intense, with numerous players vying for market share, which could pressure margins and growth.
Cencora logo

#33 - Cencora

NYSE:COR - See Stock Forecast
Stock Price:
$249.70 (+$1.25)
Market Cap:
$49.20 billion
P/E Ratio:
33.2
Dividend Yield:
0.90%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 8 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$271.20 (8.6% Upside)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cencora Stock

Pros

  • The current stock price of Cencora, Inc. is $244.60, which reflects a positive trend in the market and indicates potential for growth.
  • Recent upgrades from multiple analysts, including UBS Group and Barclays, have raised target prices significantly, suggesting strong confidence in the company's future performance.
  • Cencora, Inc. has increased its quarterly dividend to $0.55 per share, up from $0.51, which indicates a commitment to returning value to shareholders and reflects financial health.

Cons

  • The company has a high debt-to-equity ratio of 4.84, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
  • Despite recent positive developments, the stock has seen fluctuations, with a one-year low of $195.83, suggesting volatility that could deter risk-averse investors.
  • Insider selling activity, such as the recent sale of 21,509 shares by the chairman, may raise concerns about the company's future prospects from those within the organization.
Haleon logo

#34 - Haleon

NYSE:HLN - See Stock Forecast
Stock Price:
$9.73 (+$0.13)
Market Cap:
$44.02 billion
P/E Ratio:
28.6
Dividend Yield:
1.10%
Consensus Rating:
Buy (1 Strong Buy Ratings, 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$10.95 (12.6% Upside)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Haleon Stock

Pros

  • Haleon plc has a strong return on equity of 13.15%, indicating effective management and profitability relative to shareholder equity, which can attract investors looking for efficient use of capital.
  • The company reported a net margin of 9.71%, suggesting that it retains a significant portion of revenue as profit, which is a positive indicator of financial health and operational efficiency.
  • Recent analyst ratings show a consensus "Buy" rating, with several brokerages, including UBS Group, assigning a "strong-buy" rating, which reflects positive sentiment and potential for stock appreciation.

Cons

  • The company missed analysts' consensus estimates for EPS by $0.01, which may raise concerns about its ability to meet future earnings expectations.
  • Haleon plc's revenue of $3.50 billion fell short of the expected $3.55 billion, indicating potential challenges in sales performance that could affect future growth.
  • The recent dividend cut, with a payout ratio of 33.33%, may signal financial strain or a shift in company strategy, which could deter income-focused investors.
Alcon logo

#35 - Alcon

NYSE:ALC - See Stock Forecast
Stock Price:
$88.23 (+$0.99)
Market Cap:
$43.52 billion
P/E Ratio:
37.7
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$102.63 (16.3% Upside)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alcon Stock

Pros

  • Alcon Inc. has shown a strong fifty-two week performance with a growth of 26.72%, indicating positive market sentiment and potential for continued growth.
  • The current stock price is $91.98, which reflects a solid valuation in the context of its recent performance and market conditions.
  • Institutional ownership is relatively high at 72.64%, suggesting that large investors have confidence in the company's future prospects.

Cons

  • Recent short interest has increased to 4,230,000 shares, which may indicate growing skepticism among investors about the company's near-term performance.
  • The month-to-month change in shares shorted has risen by 9.59%, suggesting that more investors are betting against the stock, which could lead to downward pressure on the price.
  • Institutional ownership has decreased to 60.3%, which may reflect a lack of confidence from large investors in the company's future growth potential.
Takeda Pharmaceutical logo

#36 - Takeda Pharmaceutical

NYSE:TAK - See Stock Forecast
Stock Price:
$13.57 (+$0.13)
Market Cap:
$43.18 billion
P/E Ratio:
23.4
Dividend Yield:
3.58%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Takeda Pharmaceutical Stock

Pros

  • Takeda Pharmaceutical Company Limited has recently issued FY 2024 earnings guidance with an expected revenue of $30.1 billion, indicating strong financial performance and growth potential.
  • The company reported earnings per share (EPS) of $0.56 for the last quarter, surpassing analysts' expectations, which reflects effective management and operational efficiency.
  • As of the latest trading session, the stock price is $14.24, which is near its one-year high of $15.08, suggesting positive market sentiment and potential for further appreciation.

Cons

  • Despite recent positive earnings, the company has a relatively high debt-to-equity ratio of 0.64, which may indicate potential financial risk if the company faces downturns.
  • The stock has shown volatility, with a beta of 0.54, suggesting that it may not respond strongly to market movements, which could limit growth potential.
  • Takeda Pharmaceutical Company Limited's quick ratio of 0.77 indicates that the company may have difficulty meeting short-term liabilities, which could raise concerns about liquidity.
Seagen logo

#37 - Seagen

NASDAQ:SGEN - See Stock Forecast
Stock Price:
$228.74
Market Cap:
$42.93 billion
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Seagen Stock

Pros

  • Seagen Inc. has a strong portfolio of innovative cancer therapies, including ADCETRIS and PADCEV, which are well-established in the market and have shown significant efficacy in treating various cancers.
  • The company has a robust pipeline with promising candidates like TIVDAK and Ladiratuzumab Vedotin, which could drive future growth and revenue as they progress through clinical trials and gain regulatory approvals.
  • As of the latest data, Seagen Inc. has a stock price of $213.21, reflecting a solid performance with a 52-week increase of 62.7%, indicating strong investor confidence and market interest.

Cons

  • Seagen Inc. has experienced a month-to-month decrease in shares shorted, indicating some investor skepticism, which could reflect concerns about the company's future performance or market conditions.
  • The company has a relatively high days to cover ratio of 6.9, suggesting that it may take longer for short sellers to cover their positions, which can indicate volatility and uncertainty in the stock price.
  • Despite a strong product lineup, the biotechnology sector is highly competitive and subject to rapid changes, which can pose risks to Seagen Inc.'s market position and profitability.
Edwards Lifesciences logo

#38 - Edwards Lifesciences

NYSE:EW - See Stock Forecast
Stock Price:
$72.06 (+$0.51)
Market Cap:
$42.50 billion
P/E Ratio:
10.4
Consensus Rating:
Hold (0 Strong Buy Ratings, 10 Buy Ratings, 16 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$76.85 (6.6% Upside)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Edwards Lifesciences Stock

Pros

  • The current stock price is $70.48, which reflects a recent trading increase of 0.1%. This price point may present a buying opportunity for investors looking to enter at a favorable level.
  • Edwards Lifesciences Co. has shown a strong revenue growth of 8.9% year-over-year, indicating robust demand for its products and a solid business model.
  • Institutional investors and hedge funds own 79.46% of the company's stock, suggesting strong confidence from major financial players in the company's future performance.

Cons

  • Analysts have lowered their price targets, with UBS Group reducing their target from $90.00 to $75.00, indicating a potential decrease in expected future performance.
  • The company missed revenue expectations in its latest earnings report, generating $1.35 billion against an expectation of $1.57 billion, which may raise concerns about future growth prospects.
  • Insider selling activity has been noted, with insiders selling 40,000 shares valued at $2,657,000, which could signal a lack of confidence in the stock's short-term performance.
Alexion Pharmaceuticals logo

#39 - Alexion Pharmaceuticals

NASDAQ:ALXN - See Stock Forecast
Stock Price:
$182.50
Market Cap:
$40.34 billion
P/E Ratio:
59.6
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alexion Pharmaceuticals Stock

Pros

  • Recent acquisition by AstraZeneca for $39 billion indicates strong market confidence in Alexion Pharmaceuticals, Inc.'s value and potential for growth.
  • Current stock price reflects a significant interest from investors, suggesting a favorable market position and potential for appreciation.
  • Alexion Pharmaceuticals, Inc. has a robust pipeline of innovative therapies, which could lead to increased revenue and market share in the biopharmaceutical sector.

Cons

  • The recent data breach involving patient information could lead to reputational damage and potential regulatory scrutiny, impacting investor confidence.
  • Integration challenges following the acquisition by AstraZeneca may create operational disruptions, affecting overall performance in the short term.
  • Market volatility and economic uncertainties could pose risks to the biopharmaceutical sector, potentially impacting Alexion Pharmaceuticals, Inc.'s stock performance.
GE HealthCare Technologies logo

#40 - GE HealthCare Technologies

NASDAQ:GEHC - See Stock Forecast
Stock Price:
$83.00 (+$0.49)
Market Cap:
$37.92 billion
P/E Ratio:
22.8
Dividend Yield:
0.15%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 8 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$94.36 (13.7% Upside)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GE HealthCare Technologies Stock

Pros

  • The company reported a strong earnings per share (EPS) of $1.14 for the latest quarter, exceeding the consensus estimate of $1.06, indicating robust financial performance.
  • GE HealthCare Technologies Inc. has a solid return on equity of 25.19%, which suggests effective management and profitability relative to shareholder equity.
  • The company has announced a quarterly dividend of $0.03, translating to an annualized dividend yield of 0.14%, providing a return to investors through dividends.

Cons

  • The company’s revenue of $4.86 billion fell slightly short of analysts' expectations of $4.87 billion, indicating potential challenges in meeting market forecasts.
  • GE HealthCare Technologies Inc. has a debt-to-equity ratio of 1.12, which may raise concerns about financial leverage and the company's ability to manage its debt load effectively.
  • Despite a year-over-year revenue increase of only 0.9%, the growth may not be sufficient to attract investors looking for more aggressive expansion.
The Great AI-Energy Collision (Ad)

The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector.

Get the full story here, while you still can.
argenx logo

#41 - argenx

NASDAQ:ARGX - See Stock Forecast
Stock Price:
$614.59 (+$7.43)
Market Cap:
$37.10 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 19 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$630.42 (2.6% Upside)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of argenx Stock

Pros

  • Recent earnings report showed a significant earnings per share (EPS) of $1.39, surpassing the consensus estimate of $0.10 by $1.29, indicating strong financial performance.
  • The company generated revenue of $588.88 million, exceeding analyst expectations of $543.29 million, which reflects robust business growth and market demand for its therapies.
  • Analysts project an EPS of 2.2 for the current fiscal year, suggesting potential for continued profitability and growth in earnings.

Cons

  • Despite the positive earnings report, argenx SE has a negative return on equity of 1.45%, which indicates that the company is not generating a profit from its equity investments.
  • The company has a negative net margin of 2.11%, suggesting that it is currently spending more than it earns, which could be a concern for long-term profitability.
  • Some analysts have downgraded their ratings, with Deutsche Bank cutting its rating from "buy" to "hold," indicating a cautious outlook on the stock's performance.
ResMed logo

#42 - ResMed

NYSE:RMD - See Stock Forecast
Stock Price:
$249.33 (-$0.66)
Market Cap:
$36.60 billion
P/E Ratio:
33.0
Dividend Yield:
0.85%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 5 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$225.70 (-9.5% Downside)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of ResMed Stock

Pros

  • ResMed Inc. has recently declared a quarterly dividend of $0.53, which translates to an annualized dividend of $2.12 and a yield of 0.84%. This consistent dividend payment can provide a steady income stream for investors.
  • The company is expected to post an EPS of 9.22 for the current year, indicating strong earnings potential and growth prospects, which can attract investors looking for profitable opportunities.
  • Recent analyst ratings show a positive outlook, with several brokerages upgrading their ratings and price targets, including a "buy" rating from StockNews.com and a target price increase from Bank of America to $270.00, suggesting confidence in the company's future performance.

Cons

  • Despite the positive outlook, Wolfe Research has maintained an "underperform" rating on ResMed Inc., indicating potential concerns about the stock's performance relative to the market.
  • Insider selling has been observed, with executives selling shares worth over $14 million in the last ninety days, which could signal a lack of confidence in the stock's short-term performance.
  • The company's payout ratio is 28.08%, which, while sustainable, may limit the potential for future dividend increases, potentially disappointing income-focused investors.
IQVIA logo

#43 - IQVIA

NYSE:IQV - See Stock Forecast
Stock Price:
$201.44 (+$0.21)
Market Cap:
$36.52 billion
P/E Ratio:
26.4
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 14 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$256.50 (27.3% Upside)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IQVIA Stock

Pros

  • IQVIA Holdings Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the stock's potential for growth. Recent upgrades have set target prices as high as $300.00, suggesting significant upside from current levels.
  • The stock is currently trading at $201.82, which is well below its 12-month high of $261.73. This price point may present a buying opportunity for investors looking for value.
  • Institutional investors and hedge funds own approximately 89.62% of IQVIA's stock, reflecting strong institutional confidence and support for the company's future performance.

Cons

  • Recent selling by major shareholders, such as Victory Capital Management Inc. and BNP PARIBAS ASSET MANAGEMENT Holding S.A., may signal a lack of confidence in the stock's short-term performance.
  • Analysts have varied opinions on the stock, with some reducing their price targets significantly, such as BTIG Research lowering their target from $290.00 to $260.00, which could indicate potential volatility.
  • The stock has experienced fluctuations, with a recent trading range between a low of $187.62 and a high of $261.73 over the past year, suggesting uncertainty in its price stability.
Humana logo

#44 - Humana

NYSE:HUM - See Stock Forecast
Stock Price:
$296.83 (+$1.24)
Market Cap:
$35.74 billion
P/E Ratio:
26.3
Dividend Yield:
1.16%
Consensus Rating:
Hold (0 Strong Buy Ratings, 6 Buy Ratings, 19 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$315.86 (6.4% Upside)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Humana Stock

Pros

  • Humana Inc. has shown strong financial performance, reporting earnings per share (EPS) of $4.16, which exceeded analyst expectations by $0.68, indicating robust profitability.
  • The company has a significant market capitalization of approximately $35.90 billion, suggesting a stable and established presence in the insurance sector.
  • Recent stock trading activity shows an increase, with shares trading up 0.8% to $298.11, reflecting positive market sentiment and potential for further growth.

Cons

  • Analysts have recently downgraded their ratings on Humana, with Jefferies Financial Group lowering its rating from "buy" to "hold" and significantly reducing the price target from $519.00 to $253.00, indicating potential concerns about future performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 26.40, which may suggest that it is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Humana's stock has experienced significant volatility, with a 52-week high of $527.18 and a low of $213.31, indicating that the stock price may be subject to large fluctuations.
IDEXX Laboratories logo

#45 - IDEXX Laboratories

NASDAQ:IDXX - See Stock Forecast
Stock Price:
$421.76 (+$4.44)
Market Cap:
$34.54 billion
P/E Ratio:
40.7
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$552.38 (31.0% Upside)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IDEXX Laboratories Stock

Pros

  • IDEXX Laboratories, Inc. has recently reported strong earnings, with $2.80 earnings per share, surpassing the consensus estimate of $2.69. This indicates robust financial performance and effective management.
  • The company has a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment and potential for stock appreciation.
  • With a current stock price of approximately $418.61, there is significant upside potential as analysts have set a consensus price target of $552.38, indicating a possible increase of over 30%.

Cons

  • The stock has a high price-to-earnings (P/E) ratio of around 40.15, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • IDEXX Laboratories, Inc. has a beta of 1.36, suggesting that the stock is more volatile than the market. This could lead to larger price swings, increasing investment risk.
  • Despite recent revenue growth, the company’s quarterly revenue of $975.50 million fell short of analysts' expectations of $980.32 million, which may raise concerns about future performance.
Alnylam Pharmaceuticals logo

#46 - Alnylam Pharmaceuticals

NASDAQ:ALNY - See Stock Forecast
Stock Price:
$253.74 (+$0.39)
Market Cap:
$32.73 billion
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 18 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$298.09 (17.5% Upside)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alnylam Pharmaceuticals Stock

Pros

  • Analysts have recently upgraded their earnings estimates for FY2024, with expectations of a smaller loss per share of ($2.52) compared to previous estimates, indicating potential for improved financial performance.
  • The stock has received a significant number of buy ratings from analysts, with a consensus rating of "Moderate Buy" and an average target price of $294.50, suggesting strong market confidence in the company's future.
  • Alnylam Pharmaceuticals, Inc. has a current stock price of $250.98, which is relatively close to its 52-week high of $304.39, indicating that the stock may have room for growth.

Cons

  • The company reported a quarterly loss of ($0.87) EPS, which was significantly worse than the consensus estimate of ($0.51), indicating challenges in meeting market expectations.
  • Revenue for the latest quarter decreased by 33.3% compared to the same quarter last year, raising concerns about the company's growth trajectory and market demand for its products.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 31.64, which may indicate financial risk and could limit the company's ability to invest in future growth opportunities.
DexCom logo

#47 - DexCom

NASDAQ:DXCM - See Stock Forecast
Stock Price:
$78.10 (+$0.16)
Market Cap:
$30.51 billion
P/E Ratio:
46.8
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$104.59 (33.9% Upside)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of DexCom Stock

Pros

  • Recent analyst upgrades have increased target prices, with Sanford C. Bernstein raising their target from $82.00 to $86.00, indicating positive market sentiment and potential for stock appreciation.
  • The current stock price is $75.88, which is significantly lower than its fifty-two week high of $142.00, suggesting a potential buying opportunity for investors looking for value.
  • DexCom, Inc. has a strong market capitalization of $29.64 billion, reflecting its solid position in the medical device industry, particularly in continuous glucose monitoring systems.

Cons

  • Recent downgrades from brokerages, such as StockNews.com reducing their rating from "buy" to "hold," suggest that some analysts are cautious about the stock's near-term performance.
  • The stock has experienced a significant decline from its fifty-two week high of $142.00, which may indicate underlying issues or market volatility that could affect future performance.
  • With a P/E/G ratio of 2.33, the stock may be considered overvalued relative to its growth rate, which could deter value-focused investors.
Centene logo

#48 - Centene

NYSE:CNC - See Stock Forecast
Stock Price:
$59.92 (-$0.08)
Market Cap:
$30.25 billion
P/E Ratio:
10.4
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$83.92 (40.1% Upside)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Centene Stock

Pros

  • Centene Co. has a strong market capitalization of approximately $29.93 billion, indicating a solid position in the healthcare sector, which can attract institutional investors and provide stability.
  • The company has a relatively low price-to-earnings (P/E) ratio of 10.03, suggesting that the stock may be undervalued compared to its earnings, making it an attractive option for value investors.
  • Recent insider buying activity, including significant purchases by the CEO and CFO, indicates confidence in the company's future performance, which can be a positive signal for potential investors.

Cons

  • Analysts have recently lowered price targets for Centene Co., with some firms reducing their target from $83.00 to $66.00, indicating a lack of confidence in short-term price appreciation.
  • The stock has a beta of 0.49, suggesting lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.
  • Despite recent insider purchases, insiders only own 0.29% of the company's stock, which may indicate a lack of alignment between management and shareholder interests.
Cardinal Health logo

#49 - Cardinal Health

NYSE:CAH - See Stock Forecast
Stock Price:
$122.59 (+$0.15)
Market Cap:
$29.67 billion
P/E Ratio:
23.9
Dividend Yield:
1.66%
Consensus Rating:
Hold (0 Strong Buy Ratings, 7 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$123.00 (0.3% Upside)
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cardinal Health Stock

Pros

  • The stock is currently trading at $121.84, which is close to its 12-month high of $126.14, indicating strong market performance and potential for further growth.
  • Cardinal Health, Inc. reported earnings per share (EPS) of $1.88 for the latest quarter, exceeding analysts' expectations of $1.62, showcasing the company's ability to generate profits above market predictions.
  • The company has a consensus price target of $123.00, suggesting that analysts expect the stock to appreciate in value, which could lead to capital gains for investors.

Cons

  • The company's revenue decreased by 4.3% compared to the same quarter last year, which may indicate challenges in maintaining sales growth and could affect future profitability.
  • Cardinal Health, Inc. has a negative return on equity of 56.56%, suggesting that the company is not effectively generating profits from its equity, which could be a red flag for potential investors.
  • Despite recent upgrades, one analyst has issued a sell rating, indicating that there are differing opinions on the stock's future performance, which could create uncertainty for investors.
BioNTech logo

#50 - BioNTech

NASDAQ:BNTX - See Stock Forecast
Stock Price:
$120.72 (+$2.18)
Market Cap:
$28.94 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$138.67 (14.9% Upside)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of BioNTech Stock

Pros

  • BioNTech SE recently reported earnings per share (EPS) of $0.81, significantly exceeding analysts' expectations of a loss of $1.26, indicating strong financial performance and potential for growth.
  • The company's revenue for the quarter was $1.24 billion, far surpassing the forecast of $514.08 million, showcasing robust demand for its products and services.
  • BioNTech SE's stock price is currently at $101.87, reflecting a 2.2% increase, which may indicate positive market sentiment and potential for further appreciation.

Cons

  • Despite recent positive earnings, BioNTech SE has a negative return on equity of 2.35%, which may raise concerns about the company's ability to generate profit from its equity investments.
  • The company has a negative net margin of 15.16%, indicating that it is currently spending more to generate revenue than it is earning, which could be a red flag for potential investors.
  • Analysts forecast that BioNTech SE will post an EPS of -3.47 for the current year, suggesting ongoing challenges in achieving profitability.

(Ad)

For the first time this year, we're allowing you to unlock a lifetime subscription to Behind the Markets and receive 6 exclusive reports at the biggest discount we've ever given. In the past year, Behind the Markets subscribers saw an average of 57.54% in returns.

More Stock Ideas from MarketBeat

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas